Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004.
Horwitz, Eric M.; Levy, Lawrence B.; Thames, Howard D.; Kupelian, Patrick A.; Martinez, Alvaro A.; Michalski, Jeffrey M.; Pisansky, Thomas M.; Sandler, Howard M.; Shipley, William U.; Zelefsky, Michael J.; Zietman, Anthony L.; Kuban, Deborah A.
2006-10-01
Citation
Horwitz, Eric M.; Levy, Lawrence B.; Thames, Howard D.; Kupelian, Patrick A.; Martinez, Alvaro A.; Michalski, Jeffrey M.; Pisansky, Thomas M.; Sandler, Howard M.; Shipley, William U.; Zelefsky, Michael J.; Zietman, Anthony L.; Kuban, Deborah A. (2006). "Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004. ." Cancer 107(7): 1496-1502. <http://hdl.handle.net/2027.42/55827>
Abstract
BACKGROUND. The posttreatment prostate-specific antigen (PSA) bounce phenomenon has been recognized in at least 20% of all patients treated with radiation. The purpose of the current report was to determine if there was a difference in biochemical and clinical control between the bounce and nonbounce (NB) patients using pooled data on 4839 patients with T1-2 prostate cancer treated with external beam radiation therapy (RT) alone at 9 institutions between 1986 and 1995. METHODS. The median follow-up was 6.3 years. A posttreatment PSA bounce was defined by a minimal rise of 0.4 ng/mL over a 6-month follow-up period, followed by a drop in PSA level of any magnitude. Endpoints included no biochemical evidence of disease (bNED) failure (BF) (ASTRO definition), distant failure (DF), cause-specific failure (CSF), and overall survival (OS). Patients were stratified by pretreatment PSA, Gleason score, T stage, age, dose, and risk group. RESULTS. In all, 978 (20%) patients experienced at least 1 posttreatment PSA bounce. Within 3 subgroups (risk group, pretreatment PSA, and age), statistically significant differences of remaining bounce-free were observed on univariate analysis. Patients < 70 years had a 72% chance of remaining bounce-free at 5 years compared with 75% for older patients ( P = .04). The NB patients had 72% bNED control at 10 years compared with 58% for the bounce patients. The effect of a bounce remained statistically significant on multivariate analysis ( P < .0001). No statistically significant difference in DF, CSF, or OS was observed. CONCLUSIONS. Patients treated with external beam radiation therapy alone who experience a posttreatment PSA bounce have increased risk of BF. However, this did not translate into a difference in clinical failure with the available follow-up in the current study. Cancer 2006. © 2006 American Cancer Society.Publisher
Wiley Subscription Services, Inc., A Wiley Company
ISSN
0008-543X 1097-0142
Other DOIs
PMID
16944536
Types
Article
URI
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16944536&dopt=citationMetadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.